You are here

P&T® Journal contents for February 2007


A study that was conducted to determine the incidence of postoperative ileus found that this complication was the major cause of delay in the discharge of patients from the hospital, with annual costs totaling $1.46 billion.
Jay L. Goldstein, MD, Karl A. Matuszewski, MS, PharmD, Conor P. Delaney, MD, Anthony Senagore, MD, Evelyn F. Chiao, PharmD, MPH, Manan Shah, PharmD, PhD, Kellie Meyer, PharmD, MPH, and Thomas Bramley, RPh, PhD
Although chronic constipation is a common digestive complaint in North America, physicians and patients have very different definitions of this disorder. The authors discuss the three pathophysiological subtypes; complications; pharmacological therapies and their limitations; as well as the potential impact on quality of life and the economy.
Ashok K. Tuteja, MD, MPH, and Joseph E. Biskupiak, PhD, MBA
Meeting Highlights
The benefits of telbivudine (Tyzeka) and lamivudine (Epivir-HBV) for the treatment of chronic hepatitis B are compared.
Walter Alexander
Advances in therapies for seizure disorders are presented, including levetiracetam for elderly patients, carbamazepine for partial-onset seizures in children, pregabalin for refractory epilepsy, vigabatrin for infantile spasms, oxcarbazepine for control of seizure frequency, lacosamide for partial seizures, valproate for status epilepticus and serial attacks, and lamotrigine for tonic–clonic seizures.
Lawrence M. Prescott, PhD, and Sharon L. Prescott


David Nash, MD, MBA, provides an update on the achievements of Thomas Jefferson University’s medication quality subcommittee and its efforts to promote drug safety.
David Nash, MD, MBA
Medication Errors
Matthew Grissinger, RPh, FASCP, explains how injections of the inappropriate type of contrast media have sometimes resulted in fatalities.
Matthew Grissinger, RPh, FASCP
Prescription: Washington
Stephen Barlas discusses the shortcomings of the Medicare Prescription Drug Negotiation Act, which was passed by the House of Representatives in an attempt to address the hot topic of Medicare Part D drug pricing.
Stephen Barlas
P&T presents the latest studies and information about FDA approvals, drug indications, industry updates, and new devices.
Drug Forecast
Drs. Hilas and Ezzo review inhaled insulin powder (Exubera) for patients with diabetes.
Olga Hilas, PharmD, BCPS, CGP, and Danielle C. Ezzo, PharmD, BCPS